Effects of valproic acid on an animal model of tardive dyskinesia

Behavioural Brain Research

Volumn 142, Issue 1-2, 2003, Pages 229-233

  Peixoto, Marcello F ^a   Abílio, Vanessa C ^a   Silva, Regina H ^a   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Behavior; GABA; Rats; Reserpine; Tardive dyskinesia; Valproic acid

Indexed keywords

RESERPINE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE CALCULATION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; MALE; MOTOR ACTIVITY; MUSCLE CONTRACTION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; RAT STRAIN; TARDIVE DYSKINESIA; TIME;

EID: 0037532609     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(03)00025-1     Document Type: Article

References (40)

1. Abílio V.C., Vera J.A.R. Jr., Ferreira L.S.M., Duarte C.R.M., Carvalho R.C., Grassl C.et al. Effects of melatonin on orofacial movements in rats. Psychopharmacology. 161:2002;340-347.
2. Abílio V.C., Araujo C.C.S., Bergamo M., Calvente P.R.V., D'Almeida V., Ribeiro R. de A., Frussa-Filho R. Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry. 27:2003;109-114.
3. Andreassen O.A., Jørgensen H.Á. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Prog. Neurobiol. 61:2000;525-541.
4. Bergamo M., Abílio V.C., Queiroz C.M.T., Barbosa-Júnior H.N., Abdanur L.R.A., Frussa-Filho R. Effects of age on a new animal model of tardive dyskinesia. Neurobiol. Aging. 18:1997;623-629.
5. Calvente P.R.V., Araujo C.C.S., Bergamo M., Abílio V.C., D'Almeida V., Ribeiro R. de A.et al. The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:2002;401-405.
6. Casey D.E., Hammerstad J.P. Sodium valproate in tardive dyskinesia. J. Clin. Psychiatry. 40:1979;483-485.
7. Cassady SL, Thaker GK, Tamminga CA. GABAergic treatments for tardive dyskinesia. In: Yassa R, Nair PV, Jeste DP, editors. Neuroleptic-induced movements disorders. New York: Cambridge University Press; 1997. p. 454-69.
8. Chien C., Jung K., Ross-Townsend A. Efficacious of agents related to GABA, dopamine and acetylcholine in the treatment of tardive dyskinesia. Psychopharmacol. Bull. 14:1978;20-22.
9. Crowe B.M. Symptom control in tardive dyskinesia. Br. J. Psychiatry. 143:1983;419-425.
10. Faurbye A., Rasch P.J., Petersen P.B., Brandborg G., Pakkenberg H. Neurological symptoms in pharmacotherapy of psychosis. Acta Psychiatr. Scand. 40:1964;10-27.
11. Fisk G.G., York S.M. The effect of sodium valproate on tardive dyskinesia - revisited. Br. J. Psychiatry. 150:1987;542-546.
12. Friis T., Christensen T.R., Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. Acta Psychiatr. Scand. 67:1983;178-187.
13. Frussa-Filho R., Palermo-Neto J. Effects of single and long-term metoclopramide administration on open-field and stereotyped behavior of rats. Eur. J. Pharmacol. 149:1988;323-329.
14. Gerlach J., Casey D.E. Tardive dyskinesia. Acta Psychiatr. Scand. 77:1988;369-378.
15. Gibson A.C. Sodium valproate and tardive dyskinesia. Br. J. Psychiatry. 133:1978;82.
16. Gunne L.M., Andersson U., Bondesson U., Johanson P. Spontaneous chewing movements in rats during acute and chronic antipsychotic administration. Pharmacol. Biochem. Behav. 25:1986;897-901.
17. Gunne L.M., Haggstrom J.E., Sjokvist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in the brain GABA synthesis. Nature. 309:1984;347-349.
18. Klawans H.L. The pharmacology of tardive dyskinesia. Am. J. Psychiatry. 130:1973;82-86.
19. Levy A.D., See R.E., Levin E.D., Ellison G.D. Neuroleptic-induced oral movements in rats: methodological issues. Life Sci. 41:1987;1499-1506.
20. Linnoila M., Viukari M., Kietala O. Effects of sodium valproate on tardive dyskinesia. Br. J. Psychiatry. 129:1976;114-119.
21. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, Gilman AG, editors. The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 521-47.
22. Neisewander J.L., Castañeda E., Davis D.A. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia. Psychopharmacology. 116:1994;79-84.
23. Neisewander J.L., Castañeda E., Davis D.A., Elson H.J., Sussman A.N. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia. Eur. J. Pharmacol. 305:1996;13-21.
24. Neisewander J.L., Lucki I., McGonigle P. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res. 558:1991;27-35.
25. Neisewander J.L., Lucki I., McGonigle P. Behavioral and neurochemical effects of chronic administration of reserpirle and SKF-38393 in rats. J. Pharmacol. Exp. Ther. 257:1991;850-860.
26. Palermo-Neto J, Frussa-Filho R. Behavioural models of tardive dyskinesia in rodents: a chronological review. In: Bolis CL, Licino J, editors. Dopaminergic system: its evolution from biology to clinical aspects. Geneva: AIREN (International Association for Research and Training in Neurosciences) and World Health Organization; 2001. p. 61-81.
27. Queiroz C.M.T., Piovezani R.D., Frussa-Filho R. Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats. Eur. J. Pharmacol. 356:1998;105-108.
28. Queiroz C.M.T., Frussa-Filho R. Effects of buspirone on an animal model of tardive dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 23:1999;1405-1418.
29. Raghavendra V., Naidu P.S., Kulkarni S.K. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors. Brain Res. 904:2001;149-152.
30. Sachdev O.S. The current status of tardive dyskinesia. Aust. N. Z. J. Psychiatry. 34:2000;355-369.
31. Sasaki T., Kennedy J.L., Nobrega J.N. Localized changes in GABA receptor-gated chloride channel in rat brain after long-term haloperidol: relation to vacuous chewing movements. Synapse. 25:1997;73-79.
32. Soares KVS, McGrath JJ, Deeks JJ. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia (Cochrane review). The Cochrane Library, issue 1, Oxford; 2001.
33. Takeuchi H., Ishigooka J., Kobayashi K., Watanabe S., Miura S. Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;679-691.
34. Thaker G.K., Nguyen A.J., Tamminga C.A. Increased saccadic distractibility in tardive dyskinesia: functional evidence for subcortical GABA dysfunction. Biol. Psychiatry. 1:1988;49-59.
35. Thaker G.K., Tamminga C.A., Alphs L.D., Lafferman J., Ferraro T.N., Hare T.A. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Arch. Gen. Psychiatry. 44:1987;522-529.
36. Uhrbrand L., Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacologia. 1:1960;408-418.
37. Waddington J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophisiology and putative relationship to tardive dyskinesia. Psychopharmacology. 101:1990;431-447.
38. Waddington JL. Rodent and other animal models of tardive dyskinesia during long-term neuroleptic drug administration: controversies and implications for the clinical syndrome. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movements disorders. Cambridge: Cambridge University Press; 1997. p. 225-37.
39. Wolfarth S., Ossowska K. Can supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia? Prog. Neuropsychopharmacol. Biol. Psychiatry. 13:1989;789-840.
40. Yassa R., Nair V. The association of tardive dyskinesia and pseudoparkinsonism. Prog. Neuropsychopharmacol. Biol. Psychiatry. 12:1988;909-914.